HRSA’s Maternal and Child Health Bureau is soliciting proposals for HRSA/MCHB Newborn Screening Systematic Evidence Review IDIQ and Task Order 1 under solicitation 75R60226R00026. Proposals are due September 22, 2026 at 5:00 p.m. EDT.
What HRSA is buying
The procurement establishes a multiple-award Indefinite-Delivery, Indefinite-Quantity pool for specialized scientific methodologies, systematic clinical evidence reviews, technical expert-panel support, and programmatic services supporting the Newborn Screening Recommended Uniform Screening Panel. HRSA expects approximately three to five master IDIQ awards and will concurrently award a firm-fixed-price Task Order 1 for evidence reviews and newborn-screening processes.
Competition and eligibility
The solicitation is full and open. Qualified commercial, academic, nonprofit, and public entities may submit proposals. The procurement is classified under NAICS 541690 and PSC R499. Offerors must be able to document the specialized personnel, technical approach, and past performance required by the solicitation.
Value and term
The master IDIQ has a five-year ordering period consisting of a 12-month base period plus four sequential 12-month option periods. The aggregate collective ceiling is $15,111,361, which is an ordering ceiling and not a guaranteed award amount.
Submission requirements
Proposals must be submitted in three separate volumes: a technical proposal with a 25-page narrative limit, a past-performance volume with three prime or major-subcontractor references, and a price proposal using the mandatory government Excel pricing template. HRSA states that it intends to evaluate initial proposals without formal negotiations.
Amendment 0001
September 16, 2026 informational notice: HRSA updated the SAM.gov notice description to clarify that a lack of traditional federal prime-contractor references does not by itself make a proposal non-responsive, incomplete, or ineligible for award. HRSA expressly states that this clarification is informational only and is not a solicitation amendment. Amendment 0001 remains the latest amendment, and the final proposal deadline remains September 22, 2026 at 5:00 p.m. EDT.
HRSA posted Amendment 0001 on September 11, 2026. The amendment publishes industry Q&A, removes the prior GSA Multiple Award Schedule prerequisite, confirms the procurement is a standalone full-and-open competition, and requires use of the re-baselined Attachment 2a pricing template. The Compliance Matrix and Staff Loading Chart are page-exempt appendices to the 25-page technical narrative, 11 x 17 landscape formatting is permitted for complex charts, one Primary Principal Investigator must be designated, and the former standalone Task 8 is folded into Task 2 program management.
Client references must send completed Past Performance Questionnaires directly to HRSA by September 18, 2026 at 5:00 p.m. EDT. Final proposals remain due September 22, 2026 at 5:00 p.m. EDT. Offerors must acknowledge Amendment 0001 with the signed SF-30 in Volume III, and proposal emails over 25 MB must be split into sequential messages.
Atlas analysis
Atlas Opportunity Score: 58/100. This is a legitimate open MCHB procurement with adequate time remaining and a full-and-open competition structure. However, it requires specialized evidence-synthesis, newborn-screening, scientific-methodology, and past-performance capabilities. N9+ Fit: 8/100. The Nonagon N9+ is not a meaningful core fit because the procurement is for evidence review and program support rather than telehealth delivery, remote examination, or equipment deployment. QC Healthcare or Dr. Miltie should advance only if the required evidence-review qualifications and federal registration can be documented, or through an appropriately qualified teaming partner.
Required next action
Verify active SAM/UEI registration and documented newborn-screening or systematic clinical evidence-review past performance before treating this as a direct Dr. Miltie pursuit. If those capabilities are not documented, qualify a teaming partner rather than overstating direct eligibility or experience.